Jiangsu Qianzhikang Biological Medicine

Jiangsu Qianzhikang Biological Medicine Science and Tech Co., Ltd. is a Chinese biotechnology company focused on the development of innovative oncology therapeutics, specifically targeting the hypoxic microenvironment of solid tumors. The company utilizes a proprietary platform to engineer hypoxia-activated prodrugs (HAPs), modifying nucleoside analogs like gemcitabine with bioreducible moieties to enhance tumor-specific drug delivery and bypass metabolic resistance. By leveraging a ProTide-like phosphoramidate technology, Qianzhikang aims to increase the therapeutic index of established cytotoxic agents while minimizing systemic toxicity. Its pipeline is primarily directed at refractory malignancies, including pancreatic and liver cancers, where hypoxia is a significant driver of chemotherapy resistance.